Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017 2018

Details for Mechanism ID: 17046
Country/Region: South Africa
Year: 2014
Main Partner: Kheth'Impilo
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $9,361,890 Additional Pipeline Funding: $758,110

NOTE: The following is taken from summaries released by PEPFAR on the PEPFAR Data Dashboard. They are incomplete summary paragraphs only and do not contain the full mechanism details. When the full narratives are released, we will update the mechanism pages accordingly.

Improving patient outcomes through health systems strengthening is the goal in line with the NSP, PHC, NHI as well as the PFIP strategies. The 4 objectives have cross linkages with the SAG’s 10 Point Plan to achieve zero transmission, initiation of 80% of eligible patients onto ART, retention of 70% in care at 5 years and reducing new TB infections and deaths by 50%. These will be achieved by assessing the quality gaps as per the National core and clinical safety standards through supporting District Health Management Teams in the districts of Amajuba, ILembe, Umsunduzi and the Cape Metro. Staff transitioning, appropriate staff levels and retention are critical enablers. The use of Strategic information is strengthened through development of District M&E officers. Governance is strengthened through leadership and management skills development, district planning and target setting and mentoring on supervision using SAG mentoring guidelines. Human resource capacity is strengthened through in-service training and new skills development. Supply chain processes are strengthened by supporting the quantification, forecasting procedures, stock inventory, and medicine management processes. Community systems are strengthened by the formation of networks, coordination, partnerships between community organizations in the districts as well as training and mentoring of CCGs and wards AIDS councilors. The activities are aligned to output and outcome indicators according to the KI work plan and USAID MER framework. The program outputs are measured through data collected and reported into the DHIS. This data is reviewed monthly and quarterly at the District data meetings. KI is using the outcomes to review progress against set targets, and achievement of outcomes.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $950,000
Care: TB/HIV (HVTB) $1,169,808
Care: Pediatric Care and Support (PDCS) $1,485,184
Health Systems Strengthening (OHSS) $404,486
Testing: HIV Testing and Counseling (HVCT) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $532,391
Treatment: Adult Treatment (HTXS) $3,894,721
Treatment: Pediatric Treatment (PDTX) $925,300
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 6,047
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 2,559
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 3,300
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 1,431
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 119,782
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 33,705
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 66,571
CARE_CURR Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 21,586
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 195,700
CARE_CURR Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 59,281
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2015 195,700
CARE_CURR Sum of Aggregated Age/Sex disaggregates 2015 59,281
CARE_NEW Aggregated Age/sex: <15 Female 2015 2,780
CARE_NEW Aggregated Age/sex: <15 Male 2015 1,521
CARE_NEW Aggregated Age/sex: 15+ Female 2015 55,156
CARE_NEW Aggregated Age/sex: 15+ Male 2015 30,614
CARE_NEW Number of HIV-infected adults and children newly enrolled in clinical care during the reporting period and received at least one of the following at enrollment: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 90,071
CARE_NEW Sum of Aggregated Age/sex disaggregates 2015 90,071
CARE_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 24
CARE_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing clinical care services 2015 24
CARE_SITE By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 81
CARE_SITE By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing clinical care services 2015 100
CARE_SITE Number of PEPFAR-supported HIV clinical care sites at which at least 80% of PLHIV received all of the following during the reporting period: 1) clinical assessment (WHO staging) OR CD4 count OR viral load, AND 2) TB screening at last visit, AND 3) if eligible, cotrimoxazole 2015 105
CARE_SITE Sum of Numerator Site Support Type disaggregates 2015 105
CARE_SITE Total number of PEPFAR supported sites providing clinical care services 2015 124
CARE_SITE_den Sum of Denominator Site Support Type disaggregates 2015 124
FPINT_SITE By site support type: Direct Service Delivery (DSD): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2015 23
FPINT_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported HIV service delivery points 2015 23
FPINT_SITE By site support type: Technical Assistance-only (TA): Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2015 13
FPINT_SITE By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported HIV service delivery points 2015 101
FPINT_SITE Number of service delivery points supported by PEPFAR for HIV services that are directly providing integrated voluntary family planning services 2015 36
FPINT_SITE Service delivery type: Clinical 2015 124
FPINT_SITE Sum of Numerator Site Support Type disaggregates 2015 36
FPINT_SITE Sum of Service Delivery Type disaggregates 2015 124
FPINT_SITE Total number of PEPFAR-supported HIV service delivery points: PMTCT, Care and Treatment 2015 124
FPINT_SITE_den Sum of Denominator Site Support Type disaggregates 2015 124
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 13,212
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2015 3,808
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 7,517
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2015 2,166
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 174,896
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2015 50,444
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 112,203
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2015 32,355
HTS_TST By Test Result: Negative 2015 271,416
HTS_TST By Test Result: Negative 2015 76,513
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 307,828
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2015 88,773
HTS_TST Sum of Aggregated Age/Sex <15 2015 20,729
HTS_TST Sum of Aggregated Age/Sex <15 2015 5,974
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 287,099
HTS_TST Sum of Aggregated Age/Sex 15+ 2015 82,799
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 307,828
HTS_TST Sum of Aggregated Age/Sex disaggregates 2015 88,773
HTS_TST Sum of Test Result disaggregates 2015 307,828
HTS_TST Sum of Test Result disaggregates 2015 88,773
HTS_TST_POS By Test Result: Positive 2015 36,412
HTS_TST_POS By Test Result: Positive 2015 12,260
PMTCT_ARV Life-long ART (including Option B+) 2015 9,174
PMTCT_ARV Life-long ART (including Option B+) 2015 3,255
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 158
PMTCT_ARV Maternal AZT (prophylaxis component of WHO Option A during pregnancy and delivery) 2015 47
PMTCT_ARV Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 6,504
PMTCT_ARV Maternal triple ARV prophylaxis (provided with the intention to stop at the end of the breastfeeding period) 2015 2,862
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 15,836
PMTCT_ARV Number of HIV- positive pregnant women identified in the reporting period (including known HIV-positive at entry) 2015 6,147
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 15,836
PMTCT_ARV Number of HIV-positive pregnant women who received antiretrovirals to reduce risk of mother-to-child-transmission (MTCT) during pregnancy and delivery 2015 6,147
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 5,016
PMTCT_ARV Sub-Disag of Life-long ART: Already on treatment at the beginning of the current pregnancy 2015 1,408
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 4,158
PMTCT_ARV Sub-Disag of Life-long ART: Newly initiated on treatment during the current pregnancy 2015 1,830
PMTCT_ARV Sum of New and Current disaggregates 2015 9,174
PMTCT_ARV Sum of New and Current disaggregates 2015 3,238
PMTCT_ARV Sum of Regimen Type disaggregates 2015 15,836
PMTCT_ARV Sum of Regimen Type disaggregates 2015 6,164
PMTCT_EID By infants who received a virologic test within 2 months of birth 2015 15,426
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2015 4,872
PMTCT_EID By infants with a positive virologic test result within 12 months of birth 2015 324
PMTCT_EID Number of HIV- positive pregnant women identified during the reporting period (include known HIV-positive women at entry into PMTCT) 2015 20,297
PMTCT_EID Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2015 19,282
PMTCT_EID Sum of Infant Age disaggregates 2015 20,298
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 16
PMTCT_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 16
PMTCT_SITE By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 108
PMTCT_SITE By site support type: Technical Assistance-only (TA): Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 108
PMTCT_SITE Number of PEPFAR-supported sites achieving 90% ARV or ART coverage for HIV+ pregnant women 2015 124
PMTCT_SITE Sum of Numerator Support Type disaggregates 2015 124
PMTCT_SITE Total number of PEPFAR supported sites providing PMTCT services (HTC and ARV or ART services) 2015 124
PMTCT_SITE_den Sum of Denominator Support Type disaggregates 2015 124
PMTCT_STAT By: Known positives at entry 2015 10,212
PMTCT_STAT By: Known positives at entry 2015 2,464
PMTCT_STAT By: Number of new positives identified 2015 5,624
PMTCT_STAT By: Number of new positives identified 2015 2,275
PMTCT_STAT Number of new ANC and L&D clients 2015 65,060
PMTCT_STAT Number of new ANC and L&D clients 2015 13,123
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 65,060
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2015 12,991
PMTCT_STAT Sum of Positives Status disaggregates 2015 15,836
PMTCT_STAT Sum of Positives Status disaggregates 2015 4,739
QI_SITE By site support type: Direct Service Delivery (DSD): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months 2015 15
QI_SITE By site support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, HTC 2015 29
QI_SITE By site support type: Technical Assistance-only (TA): Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented results in the last 6 months 2015 14
QI_SITE By site support type: Technical Assistance-only (TA): Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 126
QI_SITE Number of PEPFAR-supported clinical service sites with a quality improvement activity completed that addresses clinical HIV programs and has documented process results in the last 6 months 2015 29
QI_SITE Sum of Numerator Site Support Type disaggregates 2015 29
QI_SITE Total number of PEPFAR-supported sites for any HIV clinical service including HIV Care, HIV Treatment, TB care, PMTCT, VMMC, and HTC 2015 155
QI_SITE_den Sum of Denominator Site Support Type disaggregates 2015 155
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2015 3,840
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2015 3,763
TB_ARTSITE By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units 2015 23
TB_ARTSITE By site support type: Direct Service Delivery (DSD): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 23
TB_ARTSITE By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units 2015 101
TB_ARTSITE By site support type: Technical Assistance-only (TA): The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 76
TB_ARTSITE Sum of Numerator Site Support Type disaggregates 2015 99
TB_ARTSITE The number of PEPFAR-supported TB basic management units 2015 124
TB_ARTSITE The number of PEPFAR-supported TB basic management units at which 80% of registered TB cases who are HIV-positive are on ART, during the reporting period 2015 99
TB_ARTSITE_den Sum of Denominator Site Support Type disaggregates 2015 124
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: <15 2015 5,000
TB_SCREEN Aggregated Age - USE WITH HQ PERMISSION ONLY: 15+ 2015 69,101
TB_SCREEN Number of HIV positive adults and children who received at least one of the following during the reporting period: clinical assessment (WHO staging) OR CD4 count OR viral load 2015 59,281
TB_SCREEN Sex: Female 2015 45,276
TB_SCREEN Sex: Male 2015 28,825
TB_SCREEN Sum of Aggregated Age disaggregates 2015 74,101
TB_SCREEN Sum of Sex disaggregates 2015 74,101
TB_SCREEN The number of PLHIV who were screened for TB symptoms at the last clinical visit to an HIV care facility during the reporting period 2015 56,317
TX_CURR Age/Sex: <1 Female 2015 37
TX_CURR Age/Sex: <1 Male 2015 37
TX_CURR Age/Sex: 1-4 Female 2015 268
TX_CURR Age/Sex: 1-4 Male 2015 268
TX_CURR Age/Sex: 15+ Female 2015 33,911
TX_CURR Age/Sex: 15+ Male 2015 15,977
TX_CURR Age/Sex: 5-14 Female 2015 855
TX_CURR Age/Sex: 5-14 Male 2015 855
TX_CURR Aggregated Age/Sex: <1 Female 2015 704
TX_CURR Aggregated Age/Sex: <1 Female 2015 37
TX_CURR Aggregated Age/Sex: <1 Male 2015 704
TX_CURR Aggregated Age/Sex: <1 Male 2015 37
TX_CURR Aggregated Age/Sex: <15 Female 2015 2,650
TX_CURR Aggregated Age/Sex: <15 Female 2015 1,160
TX_CURR Aggregated Age/Sex: <15 Male 2015 2,486
TX_CURR Aggregated Age/Sex: <15 Male 2015 1,160
TX_CURR Aggregated Age/Sex: 15+ Female 2015 92,904
TX_CURR Aggregated Age/Sex: 15+ Female 2015 33,911
TX_CURR Aggregated Age/Sex: 15+ Male 2015 48,176
TX_CURR Aggregated Age/Sex: 15+ Male 2015 15,977
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 146,216
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2015 52,208
TX_CURR Percent children with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 4
TX_CURR Percent women and girls with advanced HIV infection receiving antiretroviral therapy (ART) [CURRENT] 2015 65
TX_CURR Sum of age/sex disaggregates 2015 2,320
TX_CURR Sum of Aggregated Age/Sex <15 2015 5,136
TX_CURR Sum of Aggregated Age/Sex <15 2015 2,320
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 141,080
TX_CURR Sum of Aggregated Age/Sex 15+ 2015 49,888
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 146,216
TX_CURR Sum of Aggregated Age/Sex disaggregates 2015 52,208
TX_CURR_NGI Aggregated Age/Sex: <1 Female 2015 240
TX_DIST Number of Districts with documented routine supportive supervision visits to 75% of HIV care and treatment sites supported by the District 2015 4
TX_DIST Total number of PEPFAR supported District Health Offices 2015 4
TX_NEW Aggregated Grouping by Age: <1 Male 2015 40
TX_NEW Aggregated Grouping by Age/Sex: <1 Female 2015 40
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2015 150
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2015 142
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2015 5,272
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2015 2,734
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2015 8,298
TX_NEW Sum of Aggregated Age/Sex disaggregates 2015 8,298
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2015 38,258
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2015 40,272
TX_SITE By support type: Direct Service Delivery (DSD): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 23
TX_SITE By support type: Direct Service Delivery (DSD): Total number of PEPFAR-supported ART sites 2015 23
TX_SITE By support type: Technical Assistance (TA-only): Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 101
TX_SITE By support type: Technical Assistance (TA-only): Total number of PEPFAR-supported ART sites 2015 101
TX_SITE Number of PEPFAR-supported ART sites with a retention rate of 75% or greater for patients 12 months after ART initiation 2015 124
TX_SITE Sum of Numerator Site Support Type disaggregates 2015 124
TX_SITE Total number of PEPFAR-supported ART sites 2015 124
TX_SITE_den Sum of Denominator Site Support Type disaggregates 2015 124
Cross Cutting Budget Categories and Known Amounts Total: $2,637,909
Human Resources for Health $1,552,034
Gender: Gender Equality $350,000
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Capacity building
Monitoring and Evaluation
Gender: Gender Based Violence (GBV) $200,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Capacity building
Monitoring and Evaluation
Motor Vehicles: Purchased $211,400
Condoms: Policy, Tools, and Services $50,000
Food and Nutrition: Policy, Tools, and Service Delivery $274,475
Key Issues Identified in Mechanism
Child Survival Activities
Safe Motherhood
Tuberculosis
Family Planning